JP2024530839A - サポニン、オリゴヌクレオチド、およびＧａｌＮＡｃの複合体 - Google Patents

サポニン、オリゴヌクレオチド、およびＧａｌＮＡｃの複合体 Download PDF

Info

Publication number
JP2024530839A
JP2024530839A JP2023578030A JP2023578030A JP2024530839A JP 2024530839 A JP2024530839 A JP 2024530839A JP 2023578030 A JP2023578030 A JP 2023578030A JP 2023578030 A JP2023578030 A JP 2023578030A JP 2024530839 A JP2024530839 A JP 2024530839A
Authority
JP
Japan
Prior art keywords
saponin
oligonucleotide
molecule
galnac
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023578030A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024530839A5 (cg-RX-API-DMAC7.html
Inventor
ポステル，ルーベン
ヘアマンス，ガイ
デ ランゲムヒーン，ヘルムス ファン
ビルジャンド，マズダク アサディアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sapreme Technologies BV
Original Assignee
Sapreme Technologies BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/NL2021/050384 external-priority patent/WO2021261992A1/en
Priority claimed from PCT/NL2021/050549 external-priority patent/WO2022055351A1/en
Application filed by Sapreme Technologies BV filed Critical Sapreme Technologies BV
Publication of JP2024530839A publication Critical patent/JP2024530839A/ja
Publication of JP2024530839A5 publication Critical patent/JP2024530839A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023578030A 2021-06-18 2022-03-08 サポニン、オリゴヌクレオチド、およびＧａｌＮＡｃの複合体 Pending JP2024530839A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/NL2021/050384 WO2021261992A1 (en) 2020-06-24 2021-06-18 Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
NLPCT/NL2021/050384 2021-06-18
NLPCT/NL2021/050549 2021-09-09
PCT/NL2021/050549 WO2022055351A1 (en) 2020-09-10 2021-09-09 Conjugate of saponin, oligonucleotide and galnac
PCT/NL2022/050127 WO2022265493A1 (en) 2021-06-18 2022-03-08 Conjugate of saponin, oligonucleotide and galnac

Publications (2)

Publication Number Publication Date
JP2024530839A true JP2024530839A (ja) 2024-08-26
JP2024530839A5 JP2024530839A5 (cg-RX-API-DMAC7.html) 2025-03-13

Family

ID=80785160

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023578030A Pending JP2024530839A (ja) 2021-06-18 2022-03-08 サポニン、オリゴヌクレオチド、およびＧａｌＮＡｃの複合体

Country Status (4)

Country Link
US (1) US20240307545A1 (cg-RX-API-DMAC7.html)
EP (2) EP4355369B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024530839A (cg-RX-API-DMAC7.html)
WO (1) WO2022265493A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118356506A (zh) * 2023-01-17 2024-07-19 中国科学院上海药物研究所 去唾液酸糖蛋白受体配体与细胞毒素的偶联物及其应用
GB202300865D0 (en) * 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024235273A1 (zh) * 2023-05-15 2024-11-21 成都社泰医疗科技有限公司 多靶向化合物及其应用
AU2024312000A1 (en) * 2023-06-21 2026-02-05 Sapreme Technologies B.V. Pharmaceutical compositions for treatment of central nervous system disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011054811A1 (en) * 2009-11-03 2011-05-12 Santaris Pharma A/S Rna antagonists targeting hsp27 combination therapy
MX2016005855A (es) * 2013-11-14 2016-07-13 Roche Innovation Ct Copenhagen As Compuestos de conjugados antisentido de apolipoproteina b (apob).
SG11202106603UA (en) * 2018-12-21 2021-07-29 Sapreme Tech Bv Biologically active cluster of molecules
WO2022055351A1 (en) * 2020-09-10 2022-03-17 Sapreme Technologies B.V. Conjugate of saponin, oligonucleotide and galnac

Also Published As

Publication number Publication date
EP4355369C0 (en) 2025-06-18
US20240307545A1 (en) 2024-09-19
WO2022265493A1 (en) 2022-12-22
EP4355369B1 (en) 2025-06-18
EP4591938A3 (en) 2025-11-05
EP4355369A1 (en) 2024-04-24
EP4591938A2 (en) 2025-07-30

Similar Documents

Publication Publication Date Title
JP2024530839A (ja) サポニン、オリゴヌクレオチド、およびＧａｌＮＡｃの複合体
EP4171641B1 (en) Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
WO2022055351A1 (en) Conjugate of saponin, oligonucleotide and galnac
WO2021261992A1 (en) Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
EP4171643B1 (en) Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof
EP4210760B1 (en) Conjugate of saponin, oligonucleotide and galnac
HK40124033A (en) Conjugate of saponin, oligonucleotide and galnac
HK40110483A (en) Conjugate of saponin, oligonucleotide and galnac
HK40110483B (en) Conjugate of saponin, oligonucleotide and galnac
HK40091234B (en) Conjugate of saponin, oligonucleotide and galnac
HK40091234A (en) Conjugate of saponin, oligonucleotide and galnac
CN117881427A (zh) 皂苷、寡核苷酸和galnac的缀合物
HK40116734A (en) Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac oligonucleotide conjugate
AU2026202914A1 (en) Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
HK40128805A (en) Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof
HK40129944A (zh) Galnac和皂苷的缀合物、包含所述缀合物和galnac-寡核苷酸缀合物的治疗性组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250305